MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14740338.2020.1734560

Медицинская библиотека · Expert opinion on drug safety · 2020

Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.

Tzanetakou Vassiliki, Stergianou Dimitra, Giamarellos-Bourboulis Evangelos J

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Introduction

Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory skin disorder that affects regions rich in apocrine glands. Although the etiology of HS is not clear, inflammatory cytokines, like tumor necrosis factor (TNF)-α, participate in pathogenesis. Adalimumab (ADA), a human IgG1 monoclonal antibody that selectively targets TNFα, is the only EMA/FDA-approved biologic agent available for the therapy of moderate-to-severe HS.Areas covered: A comprehensive literature search was conducted to present existing studies with an emphasis on the safety profile of ADA for the treatment of moderate-to-severe HS. ADA is prescribed for more than 15 years for varied indications and has improved the therapeutic outcomes of many diseases. Clinical trials and real-life safety data from ADA administration in HS were presented, with particular attention to special populations, such as children, elderly, and pregnant women.Expert opinion: Existing data advise for limited safety concerns with long-term ADA treatment provided that patients are thoroughly screened for infections, latent tuberculosis, and history of malignancy before the start of treatment.

Для цитирования: Tzanetakou Vassiliki, Stergianou Dimitra, Giamarellos-Bourboulis Evangelos J. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.. Expert opinion on drug safety. 2020. DOI: 10.1080/14740338.2020.1734560.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.